Short Interest in Aclarion, Inc. (NASDAQ:ACON) Decreases By 73.9%

Aclarion, Inc. (NASDAQ:ACON) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 122,800 shares, a decline of 73.9% from the February 28th total of 471,200 shares. Based on an average daily volume of 4,910,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 24.3% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Several analysts have weighed in on ACON shares. Maxim Group reissued a “hold” rating on shares of Aclarion in a report on Friday, December 13th. Ascendiant Capital Markets lowered their price objective on shares of Aclarion from $502.50 to $435.50 and set a “buy” rating on the stock in a research note on Wednesday, November 27th.

Aclarion Price Performance

Shares of ACON opened at $0.58 on Thursday. Aclarion has a 1-year low of $0.49 and a 1-year high of $231.15. The firm has a 50 day simple moving average of $2.90 and a 200-day simple moving average of $36.19.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.